Article
Medicine, General & Internal
Anthony Marson, Girvan Burnside, Richard Appleton, Dave Smith, John Paul Leach, Graeme Sills, Catrin Tudur-Smith, Catrin Plumpton, Dyfrig A. Hughes, Paula Williamson, Gus A. Baker, Silviya Balabanova, Claire Taylor, Richard Brown, Dan Hindley, Stephen Howell, Melissa Maguire, Rajiv Mohanraj, Philip E. Smith
Summary: In patients with newly diagnosed focal epilepsy, levetiracetam and zonisamide were found to be not suitable as first-line treatments, with lamotrigine remaining the preferred option.
Article
Biochemistry & Molecular Biology
Davide Risso, Gillian Dunngalvin, Sameer Saxena, Andrea Doolan, Lisa Spence, Kavita Karnik
Summary: This study investigated the gastrointestinal tolerance of low-calorie sugar D-allulose in young children and found that it was well tolerated. It can be considered as a candidate for replacing added sugars with lower caloric content in commercially produced goods.
Article
Neurosciences
Maxwell J. Roeske, Maureen Mchugo, Baxter Rogers, Kristan Armstrong, Suzanne Avery, Manus Donahue, Stephan Heckers
Summary: This study found that patients with schizophrenia have hippocampal hyperactivity and the drug levetiracetam may be able to regulate hippocampal activity. Neuroimaging methods can be used to study the regulation of hippocampal hyperactivity, but not all methods are suitable. Further research is needed to establish levetiracetam as a treatment for schizophrenia.
NEUROPSYCHOPHARMACOLOGY
(2023)
Article
Nutrition & Dietetics
Meeke Ummels, Lonneke JanssenDuijghuijsen, Jurriaan J. Mes, Claire van der Aa, Ron Wehrens, Diederik Esser
Summary: This study aimed to evaluate the nutritional value of upcycled barley/rice proteins (BRP) extracted from brewers' spent grain (BSG) and compare it with pea proteins (PP). The results showed that the amino acid uptake of BRP was comparable to PP, indicating the potential for optimizing protein quality for overall health.
Article
Clinical Neurology
Valerie Cochen De Cock, Pauline Dodet, Smaranda Leu-Semenescu, Cecile Aerts, Giovanni Castelnovo, Beatriz Abril, Sophie Drapier, Helene Olivet, Anne-Gaelle Corbille, Laurene Leclair-Visonneau, Magali Sallansonnet-Froment, Marie Lebouteux, Mathieu Anheim, Elisabeth Ruppert, Nicolas Vitello, Alexandre Eusebio, Isabelle Lambert, Ana Marques, Maria Livia Fantini, David Devos, Christelle Monaca, Nicolas Benard-Serre, Sandy Lacombe, Marie Vidailhet, Isabelle Arnulf, Mohamed Doulazmi, Emmanuel Roze
Summary: This study investigated the safety and efficacy of subcutaneous night-time apomorphine infusion in treating insomnia in patients with Parkinson's disease. The results showed that this treatment significantly improved sleep disturbances and had an overall good safety profile.
Article
Rheumatology
Pascal Richette, Augustin Latourte, Jeremie Sellam, Daniel Wendling, Muriel Piperno, Philippe Goupille, Yves-Marie Pers, Florent Eymard, Sebastien Ottaviani, Paul Ornetti, Rene-Marc Flipo, Bruno Fautrel, Olivier Peyr, Jean Pierre Bertola, Eric Vicaut, Xavier Chevalier
Summary: The study found that tocilizumab was not more effective than placebo in relieving pain in patients with hand osteoarthritis. Apart from the primary endpoint, there were no significant differences in secondary outcomes between the tocilizumab group and the placebo group.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Anesthesiology
Alexa Hollinger, Christoph A. Rust, Harriet Riegger, Bianca Gysi, Fabian Tran, Jonas Brugger, Jan Huber, Katharina Toft, Madlen Surbeck, Hans-Ruedi Schmid, Katharina Rentsch, Luzius Steiner, Martin Siegemund
Summary: The Baden PRIDe trial investigated the prevention of postoperative cognitive dysfunction and delirium with the combination of haloperidol and ketamine, finding that neither was superior to placebo. Postoperative cortisol levels were significantly higher in delirious patients, while S-100 beta levels were elevated in all postoperative outcome groups and NSE levels decreased in all groups.
JOURNAL OF CLINICAL ANESTHESIA
(2021)
Article
Medicine, General & Internal
Andrew W. Horne, Stephen Tong, Catherine A. Moakes, Lee J. Middleton, W. Colin Duncan, Ben W. Mol, Lucy H. R. Whitaker, Davor Jurkovic, Arri Coomarasamy, Natalie Nunes, Tom Holland, Fiona Clarke, Ann M. Doust, Jane P. Daniels
Summary: This study evaluated whether oral gefitinib in combination with methotrexate is more effective than methotrexate alone in the treatment of tubal ectopic pregnancy. The results showed that oral gefitinib does not offer clinical benefit over methotrexate and increases minor adverse reactions.
Article
Rheumatology
Renaud Felten, Valerie Devauchelle-Pensec, Raphaele Seror, Pierre Duffau, David Saadoun, Eric Hachulla, Hatron Pierre Yves, Carine Salliot, Aleth Perdriger, Jacques Morel, Arsene Mekinian, Olivier Vittecoq, Jean-Marie Berthelot, Emanuelle Dernis, Veronique Le Guern, Philippe Dieude, Claire Larroche, Christophe Richez, Thierry Martin, Charles Zarnitsky, Gilles Blaison, Pierre Kieffer, Francois Maurier, Azeddine Dellal, Stephanie Rist, Emmanuel Andres, Anne Contis, Emmanuel Chatelus, Christelle Sordet, Jean Sibilia, Cecile Arnold, Mira Y. Tawk, Ouafaa Aberkane, Lise Holterbach, Patrice Cacoub, Alain Saraux, Xavier Mariette, Nicolas Meyer, Jacques-Eric Gottenberg
Summary: This study aimed to demonstrate the efficacy of targeting interleukin 6 receptor in patients with primary Sjogren's syndrome-related systemic complications. However, the results showed that over 24 weeks of treatment, tocilizumab did not improve systemic involvement and symptoms in patients with primary Sjogren's syndrome.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Clinical Neurology
Derrick Soh, Ricardo Maciel, Musleh Algarni, Karlo Lizarraga, Aaron Loh, Jurgen Germann, Gavin Elias, Alexandre Boutet, Renato P. Munhoz, Suneil K. Kalia, Mojgan Hodaie, Andres M. Lozano, Alfonso Fasano
Summary: The study aimed to compare the newer 8-contact linear lead connected to a 'flexible' DBS system with standard 4-contact stimulation in PD patients receiving STN DBS. Results showed a trend towards improvement in Patient Global Impression of Change scores and a significant reduction in the number of troublesome symptoms with flexible stimulation.
PARKINSONISM & RELATED DISORDERS
(2021)
Article
Medicine, General & Internal
Patricia R. M. Rocco, Pedro L. Silva, Fernanda F. Cruz, Paulo F. G. M. M. Tierno, Eucir Rabello, Jefiton Cordeiro Junior, Firmino Haag, Renata E. de avila, Joana D. G. da Silva, Mariana M. S. Mamede, Konrad S. Buchele, Luiz C. V. Barbosa, Anna C. Cabral, Antonio A. F. Junqueira, Joao A. Araujo-Filho, Lucianna A. T. J. da Costa, Pedro P. M. Alvarenga, Alexandre S. Moura, Ricardo Carajeleascow, Mirella C. de Oliveira, Roberta G. F. Silva, Cynthia R. P. Soares, Ana Paula S. M. Fernandes, Flavio Guimaraes Fonseca, Vidyleison Neves Camargos, Julia de Souza Reis, Kleber G. Franchini, Ronir R. Luiz, Sirlei Morais, Carlos Sverdloff, Camila Marinelli Martins, Nathane S. Felix, Paula Mattos-Silva, Caroline M. B. Nogueira, Dayene A. F. Caldeira, Paolo Pelosi, Jose R. Lapa-e-Silva
Summary: Nitazoxanide does not prevent admission to the intensive care unit for patients hospitalized with COVID-19 pneumonia, but it can improve clinical outcomes, reduce hospital stay, and decrease oxygen requirements.
FRONTIERS IN MEDICINE
(2022)
Article
Medicine, General & Internal
Emma Guttman-Yassky, Eric L. Simpson, Kristian Reich, Kenji Kabashima, Ken Igawa, Tetsuya Suzuki, Hirotaka Mano, Takeshi Matsui, Ehsanollah Esfandiari, Masutaka Furue
Summary: This study evaluated the efficacy and safety of the anti-OX40 antibody rocatinlimab in patients with moderate-to-severe atopic dermatitis. The results showed significant reductions in EASI score at week 16 in patients receiving rocatinlimab compared to placebo. The treatment led to progressive improvements in atopic dermatitis, which were maintained in most patients after treatment discontinuation, and it was well tolerated.
Article
Clinical Neurology
Pedro M. Machado, Michael P. McDermott, Thomas Blaettler, Claus Sundgreen, Anthony A. Amato, Emma Ciafaloni, Miriam Freimer, Summer B. Gibson, Sarah M. Jones, Todd D. Levine, Thomas E. Lloyd, Tahseen Mozaffar, Aziz Shaibani, Matthew Wicklund, Anders Rosholm, Tim Dehli Carstensen, Karen Bonefeld, Anders Norkaer Jorgensen, Karina Phonekeo, Andrew J. Heim, Laura Herbelin, Richard J. Barohn, Michael G. Hanna, Mazen M. Dimachkie
Summary: Arimoclomol did not show efficacy in individuals with inclusion body myositis compared to placebo, but it had an acceptable safety profile. This study provides valuable data on disease progression for future clinical trial designs in inclusion body myositis.
Article
Clinical Neurology
Ettore Beghi, Elisabetta Pupillo, Elisa Bianchi, Valentina Bonetto, Silvia Luotti, Laura Pasetto, Caterina Bendotti, Massimo Tortarolo, Francesca Sironi, Laura Camporeale, Alexander V. Sherman, Sabrina Paganoni, Ada Scognamiglio, Fabiola De Marchi, Paolo Bongioanni, Renata Del Carratore, Claudia Caponnetto, Luca Diamanti, Daniele Martinelli, Andrea Calvo, Massimiliano Filosto, Alessandro Padovani, Stefano Cotti Piccinelli, Claudia Ricci, Stefania Dalla Giacoma, Nicoletta De Angelis, Maurizio Inghilleri, Rossella Spataro, Vincenzo La Bella, Giancarlo Logroscino, Christian Lunetta, Claudia Tarlarini, Jessica Mandrioli, Ilaria Martinelli, Cecilia Simonini, Elisabetta Zucchi, Maria Rosaria Monsurro, Dario Ricciardi, Francesca Trojsi, Nilo Riva, Massimo Filippi, Isabella Laura Simone, Gianni Soraru, Cristina Spera, Lucia Florio, Sonia Messina, Massimo Russo, Gabriele Siciliano, Amelia Conte, Maria Valeria Saddi, Nicola Carboni, Letizia Mazzini
Summary: This study is a clinical trial on the effects of RNS60 in ALS patients. The results indicate that RNS60 has positive effects on respiratory and bulbar function, suggesting further investigation is warranted.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Richard B. Lipton, Robert Croop, David A. Stock, Jennifer Madonia, Micaela Forshaw, Meghan Lovegren, Linda Mosher, Vladimir Coric, Peter J. Goadsby
Summary: This phase 3 trial compared the efficacy, tolerability, safety, and response time of zavegepant nasal spray with placebo in the acute treatment of migraine. The results showed that zavegepant was more effective in relieving pain and symptoms than placebo, with favorable tolerability and safety profiles.
